「head」の検索結果
21件：6～10件目を表示
もしかして
-
ion for SJP-0008 as a Treatment of Central Retinal Artery Occlusion Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces tha...
https://www.senju.co.jp/sites/default/files/content_news/2024-07/ENG_20240708.pdf -
ion for SJP-0008 as a Treatment of Central Retinal Artery Occlusion Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces tha...
https://www.senju.co.jp/sites/default/files/content_news/2024-07/ENG_20240708_0.pdf -
l Co., Ltd. Launch of Distribution of Software for Dry-eye Analysis Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces the...
https://www.senju.co.jp/sites/default/files/content_news/2024-09/ENG_20240906_0.pdf -
al Co., Ltd. Acquisition of Marketing Approval for “ Mytear LUMIFY” Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida) today announces that it has received appr...
https://www.senju.co.jp/sites/default/files/content_news/2024-08/ENG_20240903.pdf -
al Co., Ltd. Acquisition of Marketing Approval for “ Mytear LUMIFY” Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida) today announces that it has received appr...
https://www.senju.co.jp/sites/default/files/content_news/2024-08/ENG_20240903_0.pdf